ALAMAST ophthalmic solution is indicated for the prevention of itching of the eye due to allergic conjunctivitis. Symptomatic response to therapy (decreased itching) may be evident within a few days, but frequently requires longer treatment (up to four weeks).

The recommended dose is one to two drops in each affected eye four times daily.

Symptomatic response to therapy (decreased itching) may be evident within a few days, but frequently requires longer treatment (up to four weeks).

ALAMAST (pemirolast potassium ophthalmic solution), 0.1% is supplied as follows:

10 mL in a white, low density polyethylene bottle with a controlled dropper tip, and a white polypropylene screw cap.

NDC 68669-711-10 10 mL fill in 10 cc container

Storage: Store at 15—25^°C (59—77^°F).

Rx only

Manufactured by:
Parkedale Pharmaceuticals, Inc., Rochester, MI 48307, USA

2.5 mL Physician Sample Manufactured by:
Santen Oy, PO Box 33
FIN-33721 Tampere, Finland
Santen®

Marketed by:
VISTAKON® Pharmaceuticals, LLC
Jacksonville, FL 32256
Licensed from Mitsubishi Pharma Corporation
Tokyo, Japan
March 2004 Version U.S. Patent No. 5,034,230
VISTAKON® Pharmaceuticals, LLC
III-03

Bookmark this page: